What do systematic reviews say?

Intervention not reported

It is very uncertain whether the intervention changes aldosterone antagonists plus loop diuretics (4 RCTs; 242 participants) (very low certainty).

• Treatment for ascites in adults with decompensated liver cirrhosis: a network meta‐analysis 2020 · Cochrane Headline outcomes only
  Rate ratio 2.04 [1.37, 3.1]
  Studies not reported
  Very low

Intervention not reported

It is very uncertain whether the intervention changes aldosterone antagonists plus loop diuretics plus paracentesis plus… (very low certainty).

• Treatment for ascites in adults with decompensated liver cirrhosis: a network meta‐analysis 2020 · Cochrane Headline outcomes only
  HR 1.24 [0.62, 2.59]
  Studies not reported
  Very low

Aldosterone antagonists vs nitrate

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs nitrate

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs nitrate

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs nitrate

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs nitrate

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs nitrate

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs nitrate

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 29 participants
  Low

Aldosterone antagonists vs nitrate

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 511 participants
  Low

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.9 [0.74, 1.11]
  3 studies · 4070 participants
  Moderate

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Mineralocorticoid receptor antagonists (MRAs) probably leads to lower heart failure hospitalisation (RR) compared with placebo or no treatment (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.82 [0.69, 0.98]
  3 studies · 3714 participants
  Moderate

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Mineralocorticoid receptor antagonists (MRAs) leads to higher hyperkalaemia compared with placebo or no treatment (high certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 2.11 [1.77, 2.52]
  6 studies · 4291 participants
  High

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in all‐cause mortality compared with placebo or no treatment (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.91 [0.78, 1.06]
  5 studies · 4207 participants
  Moderate

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in hyperkalaemia compared with selective aldosterone antagonist (low certainty).

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  RR 0.89 [0.45, 1.77]
  1 study · 1023 participants
  Low

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in death compared with selective aldosterone antagonist (low certainty).

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  RR 0.7 [0.31, 1.55]
  1 study · 1055 participants
  Low

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in doubling serum creatinine compared with selective aldosterone antagonist (low certainty).

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  RR 0.8 [0.03, 19.51]
  1 study · 1055 participants
  Low